Ensayos de fase 3
Hay ensayos aleatorizados grandes en personas en curso o publicados. No es un medicamento autorizado.
Esta página es un esbozo
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
Qué tan sólida es la evidencia
Hasta dónde ha llegado
Todo medicamento sube la misma escalera. La mayoría de los compuestos nunca llega a lo más alto, y el lugar que ocupa indica cuánto pueden sostener sus afirmaciones.
- Medicamento autorizado
Un regulador ha revisado los ensayos y lo ha autorizado para un uso concreto.
- Fase 3: Mazdutide
Ensayos aleatorizados grandes, a menudo con miles de personas, frente a placebo o un tratamiento estándar.
- Fase 2
Ensayos de tamaño medio que miden la dosis frente al efecto en personas con la enfermedad.
- Fase 1 y estudios humanos iniciales
Primeros estudios en personas: seguridad y cómo el organismo lo procesa.
- Células y animales
Trabajo de laboratorio y con animales. Un resultado en animales no es un resultado en personas.
- 58
- artículos en PubMed
- 38
- de ellos en personas
- 9
- ensayos aleatorizados
- 30
- revisiones
Un recuento indica cuánto se ha publicado, no lo que encontró. Contado en PubMed: 2026-11-16
Manipulación y reconstitución
Del polvo a una muestra medida
Los mismos cuatro pasos para cualquier vial liofilizado. Manipulación de laboratorio, no uso en una persona.
1. Lea el vial
La etiqueta indica la masa de péptido en el vial, en miligramos. Ese número es el punto de partida de todo cálculo.
2. Añada el diluyente
Se añade un volumen medido de diluyente lentamente, por la pared del vidrio. Haga girar con suavidad; agitar puede dañar un péptido.
3. Calcule la concentración
La concentración es la masa dividida por el volumen: 10 mg en 2 mL son 5 mg por mL.
4. Mida la muestra
El volumen es la masa deseada dividida por la concentración. En una jeringa U-100, 1 mL equivale a 100 unidades.
La calculadora de abajo hace la aritmética y muestra el procedimiento.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Mazdutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Mazdutide; no amount here is a recommendation.
Mazdutide: en PubMed
What PubMed held for Mazdutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 58
- papers
- 38
- in humans
- 9
- clinical trials
- 9
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
ReviewNong K, Shi Q, Xie X, et al. BMJ (Clinical research ed.), 2026. PMID 42419792
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Randomized trialJi L, Jiang H, Bi Y, et al. The New England journal of medicine, 2025. PMID 40421736
- Emerging pharmacotherapies for obesity: A systematic review
ReviewKokkorakis M, Chakhtoura M, Rhayem C, et al. Pharmacological reviews, 2025. PMID 39952695
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
Meta-analysisNalisa DL, Cuboia N, Dyab E, et al. Frontiers in endocrinology, 2024. PMID 38440786
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials
Meta-analysisAyesh H, Ayesh S, Niswender K American journal of therapeutics, 2024. PMID 39292847
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Randomized trialJi L, Jiang H, Cheng Z, et al. Nature communications, 2023. PMID 38092790
- Mazdutide: First Approval
ReviewShirley M Drugs, 2025. PMID 41028652
- Mazdutide versus placebo in Chinese adults with type 2 diabetes
Randomized trialZhu D, Zhao J, Cai H, et al. Nature, 2026. PMID 41407859
Search used: ("Mazdutide"[tiab]). Run it on PubMed
Enlaces de investigación
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Mazdutide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.